Ligand / TAP Pharmaceutical Products Collaborative Research Program
- Accelerate development and commercialization of LGD2226
- Discover and develop other orally active SARMs to treat hypogonadism, male and female sexual dysfunction, osteoporosis, frailty and male HRT
- TAP granted exclusive worldwide rights in its field
- Ligand brings SARM leadership with innovative technology, expertise, and advanced compounds, including LGD2226
- TAP brings clinical, regulatory and marketing expertise in urology, gynecology, and endocrinology